Your browser doesn't support javascript.
loading
A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.
Durbin, Anna P; Kirkpatrick, Beth D; Pierce, Kristen K; Carmolli, Marya P; Tibery, Cecilia M; Grier, Palmtama L; Hynes, Noreen; Opert, Kari; Jarvis, Adrienne P; Sabundayo, Beulah P; McElvany, Benjamin D; Sendra, Eli A; Larsson, Catherine J; Jo, Matthew; Lovchik, Janece M; Luke, Catherine J; Walsh, Mary C; Fraser, Ellen A; Subbarao, Kanta; Whitehead, Stephen S.
Afiliação
  • Durbin AP; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
  • Kirkpatrick BD; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Pierce KK; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Carmolli MP; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Tibery CM; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
  • Grier PL; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
  • Hynes N; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
  • Opert K; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
  • Jarvis AP; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Sabundayo BP; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
  • McElvany BD; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Sendra EA; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Larsson CJ; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Jo M; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
  • Lovchik JM; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
  • Luke CJ; Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.
  • Walsh MC; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Fraser EA; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Subbarao K; Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.
  • Whitehead SS; Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.
J Infect Dis ; 214(6): 832-5, 2016 Sep 15.
Article em En | MEDLINE | ID: mdl-26908742
ABSTRACT
UNLABELLED The ideal dengue vaccine will provide protection against all serotypes of dengue virus and will be economical and uncomplicated in its administration. To determine the ability of a single dose of the live attenuated tetravalent dengue vaccine TV003 to induce a suitable neutralizing antibody response, a placebo-controlled clinical trial was performed in 48 healthy adults who received 2 doses of vaccine or placebo administered 12 months apart. Evaluation of safety, vaccine viremia, and neutralizing antibody response after each dose indicated that the first dose of vaccine was capable of preventing infection with the second dose, thus indicating that multiple doses are unnecessary. CLINICAL TRIALS REGISTRATION NCT01782300.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dengue / Vacinas contra Dengue / Anticorpos Neutralizantes / Anticorpos Antivirais Tipo de estudo: Clinical_trials Limite: Adult / Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dengue / Vacinas contra Dengue / Anticorpos Neutralizantes / Anticorpos Antivirais Tipo de estudo: Clinical_trials Limite: Adult / Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2016 Tipo de documento: Article